<DOC>
	<DOC>NCT00745511</DOC>
	<brief_summary>This is s randomized, multi-center, double blind, 3 arm, phase I/II pilot study to evaluate the safety and efficacy of treatment with ORA102 combined with Avastin (Bevacizumab) versus Avastin alone, in patients with neo-vascular age related macular degeneration (AMD).</brief_summary>
	<brief_title>Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Subjects who have provided informed consent, including signing of the informed consent form Subject who are able and willing to comply with the study protocol Subject must have best corrected visual acuity ETDRS between 20/40 to 20/320 in the study eye Subjects whose CNV lesion in the study eye contains more than 25% scarring and/or atrophy Women must be postmenopausal 1 year or surgically sterilized. If not, negative serum pregnancy test required within 14 days of randomization Pregnant or lactating women Patients with severe myocardial disease or coronary occlusion Patients with severe personality disorder, suicidal risk or psychosis Patients with previous history of CVA Evidence for liver dysfunction bilirubin level more than twice than upper limit of the normal value OR ALT/AST&gt;1.5x upper limit of normal value Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the investigational drugs or puts the patients in high risk for treatment related complications</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>AMD</keyword>
	<keyword>Avastin</keyword>
	<keyword>ORA102</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>neo-vascular age related macular degeneration (AMD)</keyword>
</DOC>